Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Zabalza

Showing results (101-110 of 109) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 109 results.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 9, 2024
Secondary organising pneumonia associated to COVID-19 infection in patients with central nervous system inflammatory demyelinating diseases treated with anti-CD20 therapiesRené Carvajal, Breogán Rodríguez-Acevedo, Lorena García-Vasco, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|February 2, 2022
Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple SclerosisAna Zabalza, Georgina Arrambide, Paula Tagliani, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 29, 2025
Contribution of Blood Biomarkers to Multiple Sclerosis DiagnosisManuel Comabella, Agustín Pappolla, Enric Monreal, et al.
Multiple Sclerosis and Related Disorders|August 2, 2022
Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-βSteve Simpson-Yap, Ashkan Pirmani, Edward De Brouwer, et al.
Annals of Neurology|July 6, 2026
Assessing Progression Independent of Relapse Activity in Multiple Sclerosis Using a Patient-Reported Disability Measure and Self-Administered Neuroperformance OutcomesEvy M Reinders, Ariadna Masot-Llima, Susana Otero-Romero, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 27, 2022
Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?Ana Zabalza, Georgina Arrambide, Susana Otero-Romero, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 29, 2022
Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 SeveritySteve Simpson-Yap, Ashkan Pirmani, Tomas Kalincik, et al.
Journal of Clinical Medicine|December 11, 2022
Biopsychosocial Response to the COVID-19 Lockdown in People with Major Depressive Disorder and Multiple SclerosisSara Siddi, Iago Giné-Vázquez, Raquel Bailon, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 24, 2026
Chronological ageing and ovarian reserve in MS: insights from anti-Müllerian hormone and disability progressionAlvaro Cobo-Calvo, Juan Pablo Cuello, Enric Monreal, et al.
Pageof 11

Showing results (101-110 of 109) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 109 results.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 9, 2024
Secondary organising pneumonia associated to COVID-19 infection in patients with central nervous system inflammatory demyelinating diseases treated with anti-CD20 therapiesRené Carvajal, Breogán Rodríguez-Acevedo, Lorena García-Vasco, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|February 2, 2022
Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple SclerosisAna Zabalza, Georgina Arrambide, Paula Tagliani, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 29, 2025
Contribution of Blood Biomarkers to Multiple Sclerosis DiagnosisManuel Comabella, Agustín Pappolla, Enric Monreal, et al.
Multiple Sclerosis and Related Disorders|August 2, 2022
Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-βSteve Simpson-Yap, Ashkan Pirmani, Edward De Brouwer, et al.
Annals of Neurology|July 6, 2026
Assessing Progression Independent of Relapse Activity in Multiple Sclerosis Using a Patient-Reported Disability Measure and Self-Administered Neuroperformance OutcomesEvy M Reinders, Ariadna Masot-Llima, Susana Otero-Romero, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 27, 2022
Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?Ana Zabalza, Georgina Arrambide, Susana Otero-Romero, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 29, 2022
Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 SeveritySteve Simpson-Yap, Ashkan Pirmani, Tomas Kalincik, et al.
Journal of Clinical Medicine|December 11, 2022
Biopsychosocial Response to the COVID-19 Lockdown in People with Major Depressive Disorder and Multiple SclerosisSara Siddi, Iago Giné-Vázquez, Raquel Bailon, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 24, 2026
Chronological ageing and ovarian reserve in MS: insights from anti-Müllerian hormone and disability progressionAlvaro Cobo-Calvo, Juan Pablo Cuello, Enric Monreal, et al.
Pageof 11